Literature DB >> 17891171

Ovarian hyperstimulation induces centrosome amplification and aneuploid mammary tumors independently of alterations in p53 in a transgenic mouse model of breast cancer.

E L Milliken1, K L Lozada, E Johnson, M D Landis, D D Seachrist, I Whitten, A L M Sutton, F W Abdul-Karim, R A Keri.   

Abstract

Aneuploidy and genomic instability are common features of human cancers, including breast cancer; however, mechanisms by which such abnormalities develop are not understood. The exquisite dependence of the mammary gland on hormones for growth and development as well as hormonal contributions to breast cancer risk and progression suggest that tumorigenic mechanisms in the breast should be considered in the context of hormonal stimulation. We used transgenic mice that overexpress luteinizing hormone with subsequent ovarian hyperstimulation as a model to identify mechanisms involved in hormone-induced mammary cancer. Tumor pathology in these mice is highly variable, suggesting individual tumors undergo distinct initiating or promoting events. Supporting this notion, hormone-induced tumors display considerable chromosomal instability and aneuploidy, despite the presence of functional p53. The presence of extensive centrosome amplification in tumors and hyperplastic glands prior to tumor formation suggests that alterations in the ovarian hormonal milieu dysregulate the centrosome cycle in mammary epithelial cells, leading to aneuploidy and cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17891171      PMCID: PMC2464908          DOI: 10.1038/sj.onc.1210815

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  46 in total

1.  Altered centrosome structure is associated with abnormal mitoses in human breast tumors.

Authors:  W L Lingle; J L Salisbury
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

2.  Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome.

Authors:  C Kuperwasser; G D Hurlbut; F S Kittrell; E S Dickinson; R Laucirica; D Medina; S P Naber; D J Jerry
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

3.  Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma.

Authors:  J Bonneterre; A Buzdar; J M Nabholtz; J F Robertson; B Thürlimann; M von Euler; T Sahmoud; A Webster; M Steinberg
Journal:  Cancer       Date:  2001-11-01       Impact factor: 6.860

4.  Impact of ionizing radiation and genetic background on mammary tumorigenesis in p53-deficient mice.

Authors:  M G Backlund; S L Trasti; D C Backlund; V L Cressman; V Godfrey; B H Koller
Journal:  Cancer Res       Date:  2001-09-01       Impact factor: 12.701

Review 5.  The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting.

Authors:  R D Cardiff; M R Anver; B A Gusterson; L Hennighausen; R A Jensen; M J Merino; S Rehm; J Russo; F A Tavassoli; L M Wakefield; J M Ward; J E Green
Journal:  Oncogene       Date:  2000-02-21       Impact factor: 9.867

6.  A mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development.

Authors:  D J Jerry; F S Kittrell; C Kuperwasser; R Laucirica; E S Dickinson; P J Bonilla; J S Butel; D Medina
Journal:  Oncogene       Date:  2000-02-21       Impact factor: 9.867

7.  Normal human mammary epithelial cells spontaneously escape senescence and acquire genomic changes.

Authors:  S R Romanov; B K Kozakiewicz; C R Holst; M R Stampfer; L M Haupt; T D Tlsty
Journal:  Nature       Date:  2001-02-01       Impact factor: 49.962

8.  Centrosome amplification drives chromosomal instability in breast tumor development.

Authors:  Wilma L Lingle; Susan L Barrett; Vivian C Negron; Antonino B D'Assoro; Kelly Boeneman; Wanguo Liu; Clark M Whitehead; Carol Reynolds; Jeffrey L Salisbury
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-05       Impact factor: 11.205

9.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

Authors:  M Baum; A U Budzar; J Cuzick; J Forbes; J H Houghton; J G M Klijn; T Sahmoud
Journal:  Lancet       Date:  2002-06-22       Impact factor: 79.321

Review 10.  The chromosomal basis of cancer.

Authors:  Peter Duesberg; Ruhong Li; Alice Fabarius; Ruediger Hehlmann
Journal:  Cell Oncol       Date:  2005       Impact factor: 6.730

View more
  6 in total

Review 1.  Breast cancer and fertility preservation.

Authors:  S Samuel Kim; Jennifer Klemp; Carol Fabian
Journal:  Fertil Steril       Date:  2011-01-26       Impact factor: 7.329

2.  Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors.

Authors:  Ozgur Sahin; Qingfei Wang; Samuel W Brady; Kenneth Ellis; Hai Wang; Chia-Chi Chang; Qingling Zhang; Preety Priya; Rui Zhu; Stephen T Wong; Melissa D Landis; William J Muller; Francisco J Esteva; Jenny Chang; Dihua Yu
Journal:  Cell Res       Date:  2014-03-28       Impact factor: 25.617

3.  Mps1 as a link between centrosomes and genomic instability.

Authors:  Christopher Kasbek; Ching-Hui Yang; Harold A Fisk
Journal:  Environ Mol Mutagen       Date:  2009-10       Impact factor: 3.216

Review 4.  The relevance of mouse models to understanding the development and progression of human breast cancer.

Authors:  D Craig Allred; Daniel Medina
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-08-14       Impact factor: 2.673

5.  Mcph1/Brit1 deficiency promotes genomic instability and tumor formation in a mouse model.

Authors:  Y Liang; H Gao; S-Y Lin; J A Goss; C Du; K Li
Journal:  Oncogene       Date:  2014-11-03       Impact factor: 9.867

6.  Overexpression of WDR62 is associated with centrosome amplification in human ovarian cancer.

Authors:  Yu Zhang; Yan Tian; Jing-Jing Yu; Jie He; Jia Luo; Sai Zhang; Cen-E Tang; Yi-Ming Tao
Journal:  J Ovarian Res       Date:  2013-07-30       Impact factor: 4.234

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.